Genelux Corporation

Equities

GNLX

US36870H1032

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
3.65 ^USD	+1.39%		-4.70%	-73.95%

May. 09	Earnings Flash (GNLX) GENELUX CORPORATION Reports Q1 Revenue $8,000	MT
May. 09	Genelux Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Genelux Corporation Reports Earnings Results for the Full Year Ended December 31, 2023

March 29, 2024 at 03:01 pm EDT

Genelux Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 0.17 million compared to USD 11.07 million a year ago. Net loss was USD 28.3 million compared to USD 5.21 million a year ago.

Basic loss per share from continuing operations was USD 1.16 compared to USD 0.57 a year ago.

Latest news about Genelux Corporation

Earnings Flash (GNLX) GENELUX CORPORATION Reports Q1 Revenue $8,000	May. 09	MT
Genelux Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Genelux Insider Sold Shares Worth $256,227, According to a Recent SEC Filing	Apr. 18	MT
HC Wainwright Cuts Price Target on Genelux to $32 From $35, Maintains Buy Rating	Apr. 02	MT
Genelux Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Genelux Insider Sold Shares Worth $435,995, According to a Recent SEC Filing	Dec. 08	MT
Genelux Says FDA Grants Fast Track Designation to Potential Ovarian Cancer Treatment Olvi-Vec	Nov. 27	MT
HC Wainwright Initiates Genelux at Buy With $35 Price Target	Nov. 27	MT
Benchmark Company Adjusts Genelux Price Target to $30 From $38, Maintains Speculative Buy Rating	Nov. 24	MT
Genelux Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Genelux Insider Sold Shares Worth $110,638, According to a Recent SEC Filing	23-10-26	MT
Genelux Insider Sold Shares Worth $998,365, According to a Recent SEC Filing	23-10-25	MT
Genelux Insider Sold Shares Worth $1,929,225, According to a Recent SEC Filing	23-10-05	MT
Genelux Insider Sold Shares Worth $1,030,181, According to a Recent SEC Filing	23-09-27	MT
Genelux Insider Sold Shares Worth $300,000, According to a Recent SEC Filing	23-09-21	MT
Genelux Insider Sold Shares Worth $1,556,591, According to a Recent SEC Filing	23-09-20	MT
Genelux Corporation(NasdaqCM:GNLX) added to S&P Global BMI Index	23-09-18	CI
Genelux's Board Adopts Common Stock Grant as Inducement Plan for New Employees, Directors	23-09-14	MT
Genelux Corporation Elects John Smither as Class I Director	23-09-14	CI
Genelux Names Lourie S. Zak Chief Financial Officer	23-08-28	MT
Genelux Corporation Announces Executive Changes	23-08-28	CI
Insider Sell: Genelux	23-08-22	MT
Genelux Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Certain Convertible Promissory Notes of Genelux Corporation are subject to a Lock-Up Agreement Ending on 24-JUL-2023.	23-07-23	CI
Certain Warrants of Genelux Corporation are subject to a Lock-Up Agreement Ending on 24-JUL-2023.	23-07-23	CI

Chart Genelux Corporation

Duration

Period

More charts

Company Profile

Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patientâs tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Benchmark Healthcare House Virtual Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Genelux Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.65 USD

Average target price

26 USD

Spread / Average Target

+612.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENELUX CORPORATION	-73.95%	96.96M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs